• Drilling shows additional lithium-bearing brines carrying highly conductive zones, suggesting that lithium grades increase with depth
• Brines tested lithium grades starting at 150 mg/l, increasing to 270 mg/l when drill holes reached 250-meter contracted depth
• Results of recent drilling reinforce company’s decision to test deeper limits of aquifer
• Lithium Chile holds one of the largest lithium land holdings in Chile, a country with about 50 percent of the world’s reserves
• Global demand for lithium, which is vital to rechargeable batteries, is expected to increase by 650 percent by 2027

Mineral explorer Lithium Chile Inc. (TSX.V: LITH) (OTCQB: LTMCF) continues to announce encouraging news from its drilling program at the company’s wholly owned Ollague Project in Chile. The drilling program confirms the reliability of TEM geophysical profiles in identifying lithium-bearing brine carrying highly conductive zones and suggests that lithium grades increase with depth, according to a recent news release (http://ibn.fm/0YAJ5).

“We are extremely pleased that our drilling program continues to show good lithium grades. The fact these grades improve with the depth of the holes justify the company’s decision to target the much deeper zones on hole five,” Steve Cochrane, president and CEO of Lithium Chile, stated in the release. “It is also important to note that with the drilling of holes one and two we have identified a 4 km² zone on our southern block and with holes three and four a 10 km² zone on our larger northern block with significant lithium grades.”

Assay results from the first of four holes drilled at Ollague showed lithium concentrations on par with the average grades in Argentina, which shares the Lithium Triangle’s borders with Chile and Bolivia (http://ibn.fm/XjLi9). Samples from the fifth hole were collected from 170 meters to 350 meters and have been sent for independent analysis, the company reports.

“Drilling a fifth hole at Ollague not only reflects the encouraging data we have collected on our first four holes but also reflects our belief that Ollague has the potential to be an exciting new lithium discovery,” Cochrane added (http://ibn.fm/gZK7D).

The outlook for lithium continues to shine bright, with demand for the vital metal used to produce batteries powering electric vehicles and high-tech devices such as smartphones and laptops expected to increase 650 percent by 2027, according to Mining.com (http://ibn.fm/WTA3A). The increasing use of lithium-ion batteries in automotive applications for hybrid and fully-electric vehicles – the biggest influencer on the lithium industry in 2017 – is expected to double by 2020, according to Roskill’s 15th edition market outlook (http://ibn.fm/B4e7B).

In anticipation of the company’s next drill program getting underway soon, Lithium Chile is mobilizing a drill rig from the Ollague Project site to the Salar de Coipasa property. Coipasa is the company’s second largest property in the Andean lithium belt and is considered one of its most prospective projects.

To date, Lithium Chile owns 100 percent of 159,700 hectares of highly prospective lithium properties spread over 16 individual salars, costing the company just over $3 per hectare. That is a significant discount to recent land sales in Chile, where prospective lithium properties have sold for over $800 per hectare, as Cochrane noted in a shareholder update (http://ibn.fm/b6IPp).

For more information, visit the company’s website at http://ibn.fm/LTMCF

• Americans spending a growing amount of capital on cannabis concentrates, with forecasts for $2.9 billion in sales this year
• Cannabis Strategic Ventures recently announced the introduction of high-quality concentrate line PureOrganix in California dispensaries
• PureOrganix presence expected to gain national, international footing amid advancing tide of cannabis legalization

Cannabis industry incubator Cannabis Strategic Ventures, Inc. (OTC: NUGS) is working its way toward a national stock exchange uplisting and growing its presence within the industry through a series of timely business building ventures, including the introduction of PureOrganix, a brand marketed by subsidiary Pure Applied Sciences as a California dispensary shelf item that expects to blossom in a ready national and international market for legalized plant products.

PureOrganix is a high-quality concentrate line composed of organic and pure cannabis oils that conform to the U.S. Food and Drug Administration’s Current Good Manufacturing Practices protocols. Under a non-exclusive cannabis concentrate extraction services agreement with a U.S. subsidiary of Sunniva Inc. (CSE: SNN) (OTCQX: SNNVF), Pure Applied Sciences gets white-labeled ultra-purified cannabis extracts that the company then develops through marketing and licensing efforts for distribution to retail stores.

“Having our brand available to consumers is a huge milestone for PureOrganix,” Cannabis Strategic Ventures CEO Simon Yu stated in a news release about the product line (http://ibn.fm/HnTh0). “We have spent months refining our formulation, branding and designing our product to appeal to our target demographic… Concentrates are already revolutionizing the way cannabis is being consumed. The PureOrganix brand has already captured a strong following.”

The company cites a September 2018 market report by Arcview Market Research and BDS Analytics (http://ibn.fm/s2Efs) that Americans will spend 49 percent more on concentrates this year than they did last year, boosting concentrates’ portion of the overall cannabis market to 27 percent of sales. The report further predicts that spending on concentrates will grow from $2.9 billion this year to $8 billion by 2022, less than five years from now, following a rise of the overall market to more than $24 billion by 2021 (http://ibn.fm/RXjvl).

“Understanding this growing market segment is quickly becoming an essential part of the strategic landscape for cultivators, extractors, distributors, brands, retailers, and investors operating in the cannabis space,” the report states.

More than half of U.S. states have provided some form of legal framework for using cannabis medicinally, and the FDA’s approval of a cannabis-based drug as an anti-seizure prescription medication led the U.S. Drug Enforcement Administration to reclassify the chemical extract cannabidiol (CBD) as a nationally legal drug in FDA-approved medications last month (http://ibn.fm/M2VQQ). Canada legalized all medicinal and recreational uses of cannabis nationwide this month under locally governed frameworks (http://ibn.fm/BW1i6).

The growing legalization landscape for cannabis portends fertile ground for cannabis-related businesses. Cannabis Strategic Ventures operates out of Los Angeles as a publicly traded entity committed to acquiring, incubating, developing and partnering with companies in the startup and growth stages worldwide. Its commitment of capital and expertise to the cannabis sector and ancillary industries is in turn a vehicle for building a continually expanding portfolio of brands and hard assets to which investors in vertically integrated enterprises can turn.

For more information, visit the company’s website at www.CannabisStrategic.com

• Breast cancer is the leading cancer diagnosed in women and the second-most common cancer overall
• BriaCell Therapeutics has begun patient dosing in clinical trials that combine its trademarked Bria-IMT technology with celebrated cancer-fighting antibodies
• The clinical trials are working on a therapy that will help the body’s own immune system fight cancerous cells

The battle against breast cancer is taking a technological turn amid an increasing drive to develop therapies that use the body’s own immune system to destroy life-threatening cancer cells. BriaCell Therapeutics Corp. (OTCQB: BCTXF) (TSX.V: BCT) is on the front line of the battle and is currently testing its immuno-oncology biotechnology in phase I and IIa trials involving advanced-stage breast cancer patients.

Last month, the company announced positive outcomes from the latest proof of concept data for the study (http://ibn.fm/36wya), in which BriaCell’s trademarked Bria-IMT immunotherapy technology was checked for safety and efficacy factors in select breast cancer patients. The company reported that patients experienced some tumor shrinkage at various sites after the introduction of Bria-IMT, building on previous Bria-IMT proof of concept testing that showed substantial tumor shrinkage in a patient whose breast cancer had metastasized. In the study, blood was tested to see if cancerous cells and associated cells expressed an “immune checkpoint” molecule dubbed “programmed death-ligand 1,” or PD-L1, that might normally suppress the immune system response to cancerous “invaders.”

Earlier this month, BriaCell announced that it is proceeding with the next stage of testing — patient dosing using Bria-IMT in combination with celebrated cancer-fighting antibodies expected to increase the power of the technology’s punch (http://ibn.fm/5QKZU).

The immune checkpoint inhibiting antibodies, known as pembrolizumab and ipilimumab and marketed as Keytruda by Merck & Co., Inc. (NYSE: MRK) and as Yervoy by Bristol-Myers Squibb Company (NYSE: BMY), respectively, gained worldwide attention after the 2018 Nobel Prize in Physiology or Medicine was awarded to Drs. Tasuku Honjo and James P. Allison. Honjo and Allison made what the Nobel committee referred to as “game-changing discoveries about how to harness and manipulate the immune system to fight cancer” by studying proteins that block the immune system from attacking dangerous cells (http://ibn.fm/S30pC).

The proteins are known as CTLA-4, which Yervoy targets, and PD-1, which Keytruda targets in an attempt to “release the brakes” on the immune system’s fight against such protected cancer cells. The scientists’ work in the 1990s led rapidly to the development of new cancer therapies designed to help the body’s immune system fight off cancerous cells, and Yervoy was the first to gain approval in 2011.

Keytruda launched in 2014 and became a bigger hit. Initially, Keytruda received FDA approval for treating a type of skin cancer, but ongoing clinical trials led to its accelerated implementation in treating other forms of cancer, such as non-small cell lung cancer, head and neck squamous cell carcinoma, classical Hodgkin lymphoma and bladder cancer, with priority review currently under way for treating advanced gastric or gastroesophageal junction adenocarcinoma (http://ibn.fm/bHuRa).

In this developing landscape for battling cancer, BriaCell believes Bria-IMT’s use in stimulating the immune system’s T-cell activity, working in combination with the protein-attacking virtues of Keytruda and Yervoy, may provide the trial’s advanced-stage breast cancer patients with a greater benefit than they might otherwise have known. The PD-L1 expression of blood-borne cancer cells and cancer-associated cells suggests that Keytruda may be the best combination, and this will be evaluated initially.

Thus far in 2018, more than two million new cases of breast cancer have been diagnosed, making it the most commonly occurring cancer in women and the second most common cancer overall, according to the World Cancer Research Fund International (http://ibn.fm/HUClW).

“We believe that combination of Bria-IMT with immune checkpoint inhibitors should create even more potent anti-cancer immune responses,” BriaCell President and CEO Dr. Bill Williams stated in this month’s news release. “BriaCell is committed to exploring additional ways to address the unmet needs of the advanced breast cancer community. We are very excited to test this novel combination treatment approach which we believe will offer significant clinical benefit to patients with advanced breast cancer.”

For more information, visit the company’s website at www.BriaCell.com

• The sustainable financial growth that Sharing Services marked at the beginning of 2018 continued through the summer months
• Steady increase in both sales volume and assets reported
• The growth was accomplished through the execution of a strategic growth plan aimed at expanding Sharing Services’ range of products

Diversified holding company Sharing Services, Inc. (OTCQB: SHRV) has seen a significant rise in sales over the past three quarters. As of July 2018, the company’s sales volume has reached $12.93 million, up from $7.43 million in April and $960,000 in January 2018, according to Securities and Exchange Commission-filed financials (http://ibn.fm/pXawe).

The company’s performance has been stable, with sales not being the only metric registering steady growth. Over the past three quarters, Sharing Services also registered a rise in assets. From $78,000 in October 2017, the figure reached $2.98 million in April 2018 and $4.05 million in July 2018.

The fiscal first quarter of 2018 marked the start of the positive trend for the company. Revenue over the fiscal first quarter reached $12.9 million, a significant increase from $8.3 million over the same period of last year (http://ibn.fm/qiAVH).

This quarterly performance sets a record for Sharing Services. Since the December 2017 launch of company products through subsidiaries Elevacity Global and Elepreneur, SHRV has reported sales revenue of over $20 million.

Sharing Services CEO John Thatch stated that the company is continuously exceeding its goals as it executes its mission to change the direct-selling industry through the provision of high-quality products and services under its unique “Blue Ocean Strategy.”

Since its establishment in 2017, Sharing Services has been pursuing expansion in a couple of distinctive ways. New corporate headquarters were established to accommodate the rapid growth. Experienced talent was also brought on board to guide the strategic efforts.

At the beginning of October 2018, Sharing Services announced that marketing industry icon Larry Thompson has joined the team as the company’s new business strategist (http://ibn.fm/wFoWV). Thompson has over 50 years of experience in the direct selling/marketing fields. His mission has always been to focus on direct selling principles that enable ordinary individuals to work toward achieving both their short-term and long-term financial goals.

The Wall Street Journal described Thompson as the ‘Architect of Wealth Building’. Over the course of his career, he has been responsible for achieving more than $30 billion in sales for various companies.

Thompson will be providing strategic guidance on the launch of Elepreneurs 2.0, expected in November 2018. Elepreneurs is a wholly owned Sharing Services subsidiary. The network marketing company provides innovative entrepreneurship opportunities for home-based and independent sales representatives. It markets several brands exclusively under one unified compensation plan. These brands currently include Medical Smart Card, Elevacity Global, Hooray Health, LEH Insurance Company, Four Oceans Explorer, Total Travel Media, LD Legacy and Imagine University.

Sharing Services is a holding company that specializes in the direct selling field. It owns and controls an interest in various businesses that either sell products directly or work through independent representatives. The company provides a wide range of services that includes healthcare, insurance, wellness, travel, media, energy, technology and insurance products.

For more information, visit the company’s website at www.SHRVinc.com

• Net Element stock skyrocketed after the company announced the launch of a fully compliant payment solution for the legal cannabis industry
• Shares grew 63 percent, with volume eventually increasing to 9.5 million shares from previous full-day averages of 81,000 shares
• The payment solution enables entry into a lucrative field that’s forecast to grow beyond $22 billion by 2022

On October 22, global technology and value-added solutions group Net Element, Inc. (NASDAQ: NETE) announced the launch of a fully-compliant payment solution for the legal cannabis industry. The payment processing solution is designed to provide a smooth transaction between merchants and consumers as the popularity of cannabidiol-based products grows (http://ibn.fm/Y09oi).

Shortly after the company announced the launch of the payment solution through subsidiary Unified Payments, Net Element shares rocketed 63 percent, with volume growing to 9.5 million shares in comparison to the earlier average of 81,000 shares.

The new payment solution is complex, as it has to overcome several legal industry challenges. The legal cannabis market is dependent on state laws, because it hasn’t been allowed federally as of yet. Unified Payments had to overcome this issue through the creation of a single, unified and fully compliant product.

Previously, CBD products were mainly available in head shops. Today, they have spread to food and natural stores, beauty boutiques and even cafés. This increasing availability drives a high need for the provision of a reliable, unified payment solution.

Net Element President of Integrated Payments Vlad Sadovskiy said in a news release that the company is excited to create a legal cannabis payment acceptance solution that meets the needs of merchants across the market. Net Element works closely with numerous vendors to ensure that they’re getting access to state-of-the-art payment solutions.

The American cannabis industry is expected to grow significantly, and it will most likely reach $20 billion by the end of the year, while the hemp CBD market alone is likely to surge to $22 billion by 2022, according to cannabis and CBD research firm Brightfield Group (http://ibn.fm/B0gfM).

From 2017 to 2018, the CBD market in the U.S. nearly doubled in size, analysis suggests (http://ibn.fm/VABuF). The five-year growth projection is now dramatically higher than what experts forecast just one year previously. The prospects of full legalization of CBD products are more favorable than ever before due to the recent Hemp Farming Act of 2018 proposal aimed at removing hemp from Schedule I controlled substances and making it an agricultural commodity.

Net Element is a global financial technology and value-added solutions provider. The company supports electronic payments in an omni-channel environment. It operates a payment-as-a-service transactional model for small and medium-sized companies across the U.S. and emerging markets. The aim of the company is to utilize the model for the purpose of delivering flexible payment solutions to markets with diverse regulatory, demographic and financial transaction conditions. Net Element was ranked as one of the fastest growing North American companies on Deloitte’s 2017 Technology Fast 500.

For more information, visit the company’s website at www.NetElement.com

• New premium toolkit, which can also be installed on any website, is designed to drive website traffic, then convert visitors into customers for merchants
• Carter Chalmers, MKTDF director of sales and business development, says that the company’s new features include draw prize sweepstakes and 12 premium games for social media campaigns
• MKTDF’s gamification strategy uses surveys and games to turn unknown social media followers into identified email subscribers/paying customers and drive them to websites

DeepMarkit Corp. (TSX.V: MKT) (OTCQB: MKTDF) is taking its gamification marketing strategy to a higher level by introducing a premium toolkit laden with new features, such as social media campaigns that brand merchant clients. The conversion of that website traffic into paying customers is the goal of MKTDF’s marketing solution (http://ibn.fm/GDtPh).

“We have taken the feedback from our customers and responded with a ton of significant new features built into one premium toolkit, giving our customers a complete marketing solution for one low monthly subscription price,” Chalmers of MKTDF said in a news release.

The new toolkit is available on sites such as BigCommerce, Weebly, WordPress and Shopify, Inc. (NYSE: SHOP) (TSX: SHOP) and may also be installed on any website directly from MKTDF. The toolkit includes draw prize sweepstakes and email collection displays in the form of pop-ups, banners and full-page displays. Premium social media games are also included in the gamification strategy.

Gamification marries entertaining and engaging game-like features to a non-game platform that collects consumer data. The result is the application of real-time information and analytics created to enable retailer clients to better understand their customer bases (http://ibn.fm/iNlqQ).

MKTDF is a Calgary, Alberta-based technology company focused on the monetization of gamification. It seeks, through the prizes and discounts offered by gaming apps, to convert site visitors into loyal customers who confirm their identities as they participate. MKTDF’s revenue comes from paid gamification campaigns, as noted in MKTDF’s June 2018 investor presentation (http://ibn.fm/Nub0L).

The company’s strategy is to convert players into leads and leads into customers. Darold Parken, president and CEO of MKTDF, said in a corporate YouTube video (http://ibn.fm/upzSs), “Businesses need a way to stand out from the crowd. DeepMarkit’s gamification platform gives customers that way to stand out. And it’s a way that they can afford. That’s the strength of our platform.”

For more information, visit the company’s website at www.DeepMarkit.com

• ChineseInvestors.com reports a total year-over-year revenue increase of 70 percent for the first fiscal quarter of 2019
• The company’s current assets have nearly doubled, and its share price touched $0.90 per share as of October 17, 2018
• The agreement entered between CBD Biotechnology Co. Ltd. and Tmall is likely to boost industrial hemp CBD sales
• With products on Tmall, CBD Biotechnology Co. Ltd is positioned to cash in on Double 11 and Double 12 shopping festivals

ChineseInvestors.com, Inc. (OTCQB: CIIX) recorded impressive first quarter financial results for its fiscal year 2019. Its total revenue, comprising product sales revenue and subscription revenue, is on the uptrend.

According to Chief Executive Officer Warren Wang, cannabidiol (CBD) hemp sales in China are a major contributor to the growth in the product revenue. On the subscription services front, the company recorded a revenue increase of close to 100 percent. The steady revenues are expected to continue, buoyed by the company’s newly-introduced cryptocurrency market educational services.

In terms of liquidity, the company reported a two-fold increase in cash and cash equivalents from $1.4 million to $3 million. This pushed up the company’s total current assets to $5.5 million. On the equity side, the closing market value of common stock as of October 17, 2018, was $0.90 per share.

The outlook according to Wang is positive, thanks to the evolving business, regulatory and political landscapes of the Chinese industrial hemp CBD market. The company plans to increase its product distribution in both the U.S. and Chinese markets.

To widen the distribution network for its industrial hemp CBD products, ChineseInvestors.com, through subsidiary CBD Biotechnology Co. Ltd., signed an agreement with Alibaba Group’s Tmall. This will see the subsidiary leverage Tmall’s e-commerce marketplace to reach a wider market.

Alibaba Group (NYSE: BABA) has a total of 500 million registered customers across Tmall and Taobao. By listing its CBD skincare products on the Tmall platform, CBD Biotechnology Co. Ltd. will automatically expand its footprint.

The move comes at just the right time to take advantage of Double 11 and Double 12 shopping festivals, which take place between November and December. During this period, China records the highest volume of sales through online retailers. In 2017, the Double 11 shopping festival recorded a hopping 168.2 billion RMB ($24.2 billion) in sales in a single day.

While CBD Biotechnology Co. Ltd. isn’t the only company that produces and markets CBD skincare products in the Chinese market, it is the first to enter Tmall. The main target market for the CBD skincare products is the cosmetics industry, which is coming up strongly in China.

To further boost sales and strengthen its brand influence, the company plans to spend 2.5 million RMB ($360,000) in advertising and online marketing. This will cover all of its CBD skincare product lines.

Tmall is regarded highly as an e-commerce platform, and hundreds of companies are always applying to be authorized. Therefore, CBD Biotechnology Co. Ltd. considers itself successful for getting this opportunity. The company’s projections for total sales from October 2018 to September 2019 is 12 million RMB ($1.7 million).

ChineseInvestors.com is a financial news media platform, with headquarters in San Gabriel, California, catering to the Chinese-speaking community, not just in China, but in the United States, Canada and other parts of the world. Leveraging the platform, the company is regularly introducing other products and services such as industrial hemp CBD that are of benefit to its target market. It is also the first publicly traded company in the United States that promotes hemp-derived CBD products for the Chinese market.

For more information, visit the company’s website at www.ChineseInvestors.com

• The two new patents are related to certain cannabinoid-infused beverage compositions using LXRP’s DehydraTECH technology
• Globally, LXRP has filed some 50 patent applications as the company expands its IP portfolio; LXRP hopes to receive two more granted patents from Australia by year end, giving it 12 in total
• LXRP out-licenses its technology, which promotes healthier and faster ingestion; the company seeks accelerated patent application examinations in Australia based on the U.S. patents

Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) has been granted two new U.S. patents based on cannabinoid-infused beverage compositions using its DehydraTECH ingestion technology platform. The company is building its strategic intellectual property (IP) portfolio with over 50 applications worldwide and is seeking expedited examination for two more patents in Australia based on the U.S. patents it received. It hopes to be granted two new corresponding Australian patents by year’s end (http://ibn.fm/JOlXg).

If all are issued, LXRP will then hold 12 issued patents within its first patent family, “Food and Beverage Compositions Infused With Lipophilic Active Agents and Methods of Use Thereof.” It would strengthen LXRP’s IP claims in both countries. The two new U.S. patents granted are numbers 10,103,225 and 10,084,044.

Based in British Columbia, Canada, LXRP is a biotechnology company that has developed technology which has proven faster and more effective delivery of cannabinoids in human clinical studies and nicotine in animal laboratory studies. Its IP portfolio already includes patents for oral delivery of all cannabinoids. The newest patents are to protect LXRP’s cannabinoid-infused beverage compositions. The compositions use both non-psychoactive cannabinoids, such as CBD, and also psychoactive cannabinoids, such as THC.

LXRP has a growing IP portfolio and will license in any of the countries worldwide where its technology already has a patent or is patent-pending. DehydraTECH is its proprietary absorption technology platform.

LXRP has now filed a total of more than 50 patent applications across 10 current patent families. It is preparing applications for at least six more patents that will each form the basis for a separate patent family. It expects to file them before the end of this year, giving it management over a total of 16 patent families. The company anticipates that numerous patents will be granted within each of these families (http://ibn.fm/NMrUd).

For more information, visit the company’s website at www.LexariaBioscience.com

• Bankcard fraud to cross $6 billion in 2018
• TrustGateway blockchain technology uses biometrics to block fraud
• System under consideration by two major U.S. commercial banks

The maturation of ecommerce has been a boon to consumers everywhere, turning the world into one global marketplace. Now, though you live in America, you can order goods from China; you can shop on Amazon even though you live in the Himalayas (http://ibn.fm/M0seX). Naturally, such trade involves customer-not-present (CNP) transacting, which is providing great opportunity for fraud. CNP fraud accounts for 70 percent of card fraud (http://ibn.fm/kvPPx). For 2018, it is projected to reach $6.4 billion in the U.S. alone, which, perhaps, is why two major U.S. commercial banks and one of the largest payment infrastructural platforms in the country are taking a look at a novel solution offered by GreenBox POS, LLC (OTC: GRBX). The company has developed a payment gateway – TrustGateway – that blocks CNP fraud with blockchain technology. The gateway is a major component of the company’s QuickCard payment system and is proving to be highly efficient in preventing fraud on the GreenBox payment platform.

Buying online with a bankcard is generally a smooth, seamless process, but behind the scenes, there’s a lot going on, some of which involves a “payment gateway.” After a purchaser submits his or her debit or credit card information to a merchant online, the payment gateway sends that information, together with the amount to be charged, to the credit card payment network for processing. At present, the three largest are Visa, MasterCard and Chase. Naturally, the payment gateway is not a one-way conduit. It transmits the response from the card network back to the merchant, typically with a cryptic “approved” or “declined” message.

Such gateways are no match for someone using a stolen card or card information that has been filched, but GreenBox’s TrustGateway may just be, since it uses a number of authenticating factors. These include internet protocol (IP) correlations, location data and biometrics. To succeed in penetrating TrustGateway, a malefactor would need to take on the cardholder’s personality. GreenBox is able to provide a system with greater security since it owns all the parts that make the blockchain payment system – from TrustKeys to ledger and gateway. TrustGateway also takes part in load balancing. It maximizes system uptime and can be integrated into the QuickCard payment system and GreenBox platform.

The GreenBox POS (point-of-sale) platform is the foundation for the entire GreenBox product line, including LOOPZ and QuickCard. LOOPZ is a delivery software solution, which has three essential elements: a back-end dispatcher and two mobile apps, one for drivers and one for consumers. The LOOPZ standalone back-end dispatcher is the backbone of the system. It controls functions like accepting orders, managing drivers, setting payments, tracking deliveries and much more. The dispatching works through an SAAS engine, so there is no installation, backup or data restoration required. All of the software is supported by table and phone apps, making it easy for management on the go. With the app, drivers have access to the built-in advanced dashboard that ensures that every delivery is completed smoothly. On the consumer side, customers connect directly to merchants and are updated in real-time, guaranteeing peace of mind.

The QuickCard payment system consists of an app, an e-wallet and a kiosk. The QuickCard app allows a customer to load currency onto his or her e-wallet from a credit card or linked bank account. Customers can also link to a QuickCard kiosk installed by a merchant, which allows them to shop at that retail outlet, online or anywhere that accepts e-wallet transactions. Purchasing goods is easy with QuickCard. The customer simply enters the transaction amount and with a single click, QuickCard generates a QR code. The code is scanned by the merchant, and the funds are transferred immediately and securely, with a record being stored on the app. With TrustGateway integrated into the QuickCard payment system, consumers and merchants will have the assurance of safer transacting.

For more information, visit the company’s website at www.GreenBoxPOS.com

• SeeThruEquity revised its initial price target for American Premium Water on the basis of new company developments and strategic market positioning
• The launch of LALPINA Hydro CBD and the subsequent distribution of the product will enable the company to enter the rapidly-growing CBD market
• New research report suggests that CBD market could grow to an astounding $22 billion by 2022

American Premium Water Corp. (OTC: HIPH) announced on October 10, 2018, that independent equity research firm SeeThruEquity has revised its initial price target upward. The revision corrected the original $0.15 target to $0.30, the company said in a press release (http://ibn.fm/W5F0G). According to the SeeThruEquity report, one of the main reasons behind the price target revision is the launch of LALPINA Hydro CBD, a technically superior cannabidiol-infused beverage, which will enable the company to target large consumer opportunities.

The subsequent distribution of the CBD beverage, as well as the strategic American Premium Water deals aimed at expanding the company’s presence on the luxury markets, have also been quoted as reasons for the target revision.

According to American Premium Water CEO Ryan Fishoff, the revised target validates all of the company’s strategic efforts. Over the past year, the company has entered one of the most rapidly evolving American economic sectors – the CBD market. As a result, the company has managed to significantly reduce debt, enter substantial distribution agreements and position itself for sustainable growth in the future.

The launch of the CBD beverage enables the company to participate in a fast-growing market that is anticipated to outpace the cannabis industry within the next few years. While Greenwave Advisors estimates that the CBD market will reach $3 billion by 2021 and The Hemp Journal anticipates the increase to slightly exceed $2 billion (http://ibn.fm/rjBWD), a new report by the Brightfield Group forecasts significantly higher growth, estimating that the hemp-CBD market alone could hit $22 billion by 2022 (http://ibn.fm/B3c1v).

The revised SeeThruEquity initial price target represents a potential upside of 471.4 percent from HIPH’s recent price of $0.0525 per share, reported a day before the announcement, on October 9, 2018.

The report further highlights the fact that the company will also potentially benefit from a recent Drug Enforcement Administration (DEA) action that removes CBD as a Schedule 1 drug whenever the trace amount of THC remains below 0.1 percent. In such instances, the product will be classified as a Schedule 5 drug, following FDA approval. This change may enable additional growth in the field of pharmacology.

LALPINA Hydro CBD contains no detectable amounts of THC, which means that American Premium Water Corp. could now be able to explore the medical potential of the formulation via partnerships with industry representatives.

LALPINA Hydro CBD mixes hydro with nanotechnology to deliver hydro-infused CBD water to consumers. The company started offering the new product via its website on August 27, 2018. The nanotechnology in LALPINA Hydro CBD enables a quicker absorption rate in comparison to other CBD-infused waters. On October 17, the company announced that it had developed a prototype THC-infused beverage utilizing the same technology.

The product ensures proper hydration, and it could also be utilized by active individuals to ensure muscle relief. CBD is an excellent choice for quick workout recovery due to its analgesic, anti-inflammatory, anti-spasm and neuroprotective properties.

American Premium Water Corporation is a California-based company that maintains a portfolio of subsidiaries catering to the health and luxury goods markets. The company’s two primary pillars are the development of health and beauty biotechnology for the purpose of unlocking the full potential of hydrogen and nanotechnologies, in combination with CBD.

For more information, visit the company’s website at www.AmericanPremiumWater.com